Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, announces that Dr Daniel Gare has joined Avacta Life Sciences’ business development team effective as of 21st September.Dr Gare joins Avacta from Abcam plc (“Abcam”) where he was Head of Strategic Accounts Europe with commercial responsibility for custom products across Europe.
Dr Gare is an experienced business development specialist with a proven track record in driving sales and developing new opportunities in the pharmaceutical, biotech and academic sectors. His role at Abcam was focused on identifying and evaluating licencing opportunities to drive revenue and expand brand presence and awareness and on the commercialisation of bespoke, bulk and custom products including Epitomics’ RabMabs. Dr Gare has significant experience and knowledge relevant to the commercialisation of Affimer technology, Avacta’s engineered alternative to antibodies.
Prior to his period of employment at Abcam, Dr Gare held key roles in Roche Diagnostics UK where he undertook the responsibility for sales of the Translational Diagnostics (TDx) product line in the UK, Ireland and the Nordic countries. Daniel holds a BSc (Hons) degree in biology from Imperial College, London and a PhD from the University of Aberdeen.
Commenting on the appointment, Alastair Smith, CEO of Avacta said: “I am absolutely delighted that Dan is joining the business development team at Avacta Life Sciences to commercialise Affimer technology. He has a proven track record in the sector and, after a number of years at Abcam, brings a wealth of experience and knowledge about the market demand for affinity reagents as well as an excellent commercial network. This is an important appointment for the Group and the fact that we are attracting such high calibre individuals is a further validation of the commercial opportunity for Affimer technology.”